CareDx (CDNA) Resumen de Acciones
CareDx, Inc. ofrece soluciones para mejorar los resultados de los pacientes trasplantados y hacer avanzar la salud de los órganos en Estados Unidos y a escala internacional. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 3/6 |
| Crecimiento futuro | 0/6 |
| Rendimiento pasado | 5/6 |
| Salud financiera | 6/6 |
| Dividendos | 0/6 |
Recompensas
Análisis de riesgos
CDNA Community Fair Values
Create NarrativeSee what 12 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de CareDx, Inc.
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$46.69 |
| Máximo en las últimas 52 semanas | US$49.76 |
| Mínimo de 52 semanas | US$11.27 |
| Beta | 2.42 |
| Cambio en 1 mes | 63.77% |
| Variación en 3 meses | 116.66% |
| Cambio de 1 año | 290.06% |
| Variación en 3 años | 424.61% |
| Variación en 5 años | -33.16% |
| Variación desde la OPV | 366.90% |
Noticias y actualizaciones recientes
Recent updates
Artículo de análisis • Aug 07
Statutory Earnings May Not Be The Best Way To Understand CareDx's (NASDAQ:CDNA) True Position
CareDx, Inc. ( NASDAQ:CDNA ) recently released a strong earnings report, and the market responded by raising the share...
Actualización de narrativa • Jul 27
CDNA: Final Medicare Coverage For Transplant Testing Will Shape Balanced 2026 Repricing
Analysts have raised their fair value view on CareDx stock from $27.80 to $35.40, citing higher price targets linked to what they describe as favorable final Medicare local coverage decisions for the company’s transplant testing portfolio. Analyst Commentary Recent analyst commentary on CareDx centers on the final Medicare local coverage decisions for solid organ transplant molecular testing and what those decisions could mean for the stock’s valuation and future execution.Seeking Alpha • Jul 20
CareDx's Growth Prospects With Naveris Keep Me Bullish
Summary CareDx has a transplant-testing franchise that taps into recurring surveillance demand and has deeper integration into transplant centers. I also think CDNA’s AlloHeme gives them longer-term optionality in post-cell-therapy monitoring. More recently, CDNA sold Lab Products and purchased Naveris. These major strategic M&A deals mean CDNA now has a potential growth engine in oncology. However, I reckon CDNA’s valuation is relatively expensive. But despite that concern, I think its long-term growth justifies the stock as a speculative “Buy” today. Read the full article on Seeking AlphaActualización de narrativa • Jul 13
CDNA: Portfolio Shift To Oncology And Core Testing Will Shape 2026 Repricing
Analysts have adjusted their price target for CareDx to $27.80 from $25.80, citing updated assumptions around fair value and future P/E expectations. What’s in the News for CareDx CareDx completed the acquisition of Naveris, adding the NavDx blood based test for detecting molecular residual disease in HPV driven head and neck and anal cancers to its portfolio, according to recent news reports.
Actualización de narrativa • Jun 29
CDNA: Clinical Data And Capital Returns Will Shape Balanced Future Upside
Analysts have nudged their CareDx fair value estimate up by $2 to $28, citing updated assumptions on growth, profitability, and future P/E as the key drivers behind the higher price target. What’s in the News for CareDx CareDx shares rose 11.5% after publication of new Kidney Allograft Outcomes AlloSure Registry data in the Journal of the American Society of Nephrology.Artículo de análisis • Jun 21
CareDx (CDNA) Stock Could Be 1.5% Overvalued After AlloSure Study Buzz
CareDx (CDNA) is back in focus after fresh data from the Kidney Allograft Outcomes AlloSure Registry and a major nephrology journal publication highlighted the clinical use of its AlloSure test for transplant monitoring. See our latest analysis for CareDx. The recent AlloSure data release and upcoming American Transplant Congress presentations appear to have coincided with building momentum in CareDx, with an 11.5% 1 day share price return and a 21.04% 30 day share price return feeding into a...
Actualización de narrativa • Jun 15
CDNA: Oncology Expansion And Legal Resolution Will Shape Balanced 2026 Outlook
Analysts have raised their CareDx price target by $2, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E, which together support a modestly higher valuation. What's in the News CareDx reported Q1 revenue growth of 39% year over year, with Testing Services volume up 17%, and raised full year 2026 guidance to US$447 million to US$465 million in revenue and adjusted EBITDA of US$43 million to US$57 million, according to recent company updates.Actualización de narrativa • Jun 01
CDNA: Higher 2026 Revenue Outlook And Legal Overhang Resolution Will Drive Repricing
Analysts have lifted their price target on CareDx by $1, based on updated assumptions for fair value, discount rate, revenue growth, profit margins, and a higher future P/E, as reflected in recent BTIG research. What's in the News CareDx reported that a qui tam action filed in February 2021 was dismissed by the United States District Court for the Eastern District of New York on April 23, 2026, with no monetary payment required, after the Department of Justice concluded its investigation in October 2024 without any finding of wrongdoing and declined further action.Actualización de narrativa • Apr 27
CDNA: Wider 2026 Revenue Outlook And CMS Overhang Will Drive Repricing
Analysts have raised their average price target on CareDx by $1 to $26 per share, citing a solid Q4, a wide but above-consensus 2026 revenue outlook, and a view that the stock still appears inexpensive even with ongoing uncertainty around the CMS outcome. Analyst Commentary Recent Street commentary highlights a mix of optimism around CareDx's execution and revenue outlook, alongside ongoing caution tied to policy risk.Actualización de narrativa • Apr 13
CDNA: Wider 2026 Guide And CMS Overhang Will Drive Repricing
Analysts have lifted their price target on CareDx by $1 to $26, citing a solid Q4, a 2026 revenue outlook set above Street estimates, and a view that shares look inexpensive even with ongoing CMS uncertainty. Analyst Commentary Street research points to a mixed but generally constructive view on CareDx, with analysts weighing a solid recent quarter and new long term revenue guidance against ongoing policy risks and execution questions.Actualización de narrativa • Mar 30
CDNA: Final MolDX LCD Decision Will Drive 2026 Outlook And Upside Potential
Narrative Update on CareDx Analysts have raised their implied fair value estimate for CareDx to $21.00 from $20.00. This reflects updated views on 2026 revenue guidance, reimbursement uncertainty and the stock's valuation relative to recent Street research commentary.Actualización de narrativa • Mar 16
CDNA: Wider 2026 Outlook And CMS LCD Overhang Will Drive Repricing
The analyst price target for CareDx has shifted from $23 to $24.80, as analysts balance a wider 2026 revenue outlook and recent Q4 performance against ongoing uncertainty around the final CMS LCD and its impact on long term growth. Analyst Commentary Recent Street commentary reflects a split view on CareDx, with some analysts focusing on upside tied to execution and valuation, while others emphasize uncertainty around reimbursement and longer term growth.Actualización de narrativa • Mar 02
CDNA: Final MolDX LCD Outcome Will Shape Appeal Despite 2026 Guidance
The analyst price target for CareDx has been raised from $18 to $20. Analysts point to a higher assumed revenue growth outlook, a slightly higher future P/E, and management's 2026 revenue guidance, while still flagging uncertainty around the final CMS LCD and its impact on longer term growth and volumes.Actualización de narrativa • Feb 16
CDNA: MolDX LCD Outcome Will Temper Appeal Despite Solid 2025 Guidance
Analysts have lowered their outlook on CareDx, reducing the price target to $26. They see a less compelling risk reward profile given uncertainty around the final MolDX LCD and how it could affect 2026 revenue, longer term growth, and near term test volumes.Actualización de narrativa • Feb 01
CDNA: Reimbursement Outcomes Will Drive Future Upside Despite Cautious Rating
Analysts have trimmed their fair value estimate for CareDx from US$28 to US$26, citing a less compelling risk reward outlook as revenue and longer term growth now appear more closely tied to uncertain reimbursement outcomes and a much higher assumed future P/E. Analyst Commentary Recent research points to a more cautious stance on CareDx, with the key concern being how much future revenue and growth now hinge on reimbursement decisions and a higher assumed future P/E multiple.Actualización de narrativa • Jan 18
CDNA: MolDX LCD Uncertainty Will Restrain Appeal Despite Raised Guidance
Narrative Update on CareDx The analyst price target for CareDx has been reset to US$18.00. This reflects what analysts see as a less compelling risk reward profile, given uncertainty around future revenue tied to the final MolDX LCD and the possibility that upcoming estimates and longer term growth expectations may be too optimistic.Actualización de narrativa • Jan 04
CDNA: Raised Guidance And Share Buyback Will Shape Balanced Outlook
Analysts have raised their price target on CareDx from 14 dollars to 18 dollars, citing expectations for stronger revenue growth and a higher future earnings multiple, despite a modestly higher discount rate and lower projected profit margins. What's in the News Shareholder derivative lawsuits against current and former directors are moving toward a proposed global settlement, with a final approval hearing scheduled for June 30, 2026 in the U.S. District Court for the Northern District of California (shareholder litigation notice).Actualización de narrativa • Dec 17
CDNA: Raised Revenue Outlook And Buyback Activity Will Support Bullish Repricing
Analysts have nudged their price target on CareDx higher from around 21.83 dollars to 23.00 dollars, citing expectations for slightly faster revenue growth and a richer future valuation multiple, despite a more conservative view on long term profit margins and discount rates. What's in the News The board amended and restated company bylaws to adopt a majority voting standard for director elections, with plurality voting only in contested elections (company bylaws filing).Artículo de análisis • Nov 29
CareDx, Inc's (NASDAQ:CDNA) Shares Bounce 25% But Its Business Still Trails The Industry
CareDx, Inc ( NASDAQ:CDNA ) shares have continued their recent momentum with a 25% gain in the last month alone...Artículo de análisis • Nov 12
We Believe CareDx's (NASDAQ:CDNA) Earnings Are A Poor Guide For Its Profitability
CareDx, Inc ( NASDAQ:CDNA ) recently released a strong earnings report, and the market responded by raising the share...Artículo de análisis • Sep 19
CareDx, Inc's (NASDAQ:CDNA) Share Price Boosted 28% But Its Business Prospects Need A Lift Too
Those holding CareDx, Inc ( NASDAQ:CDNA ) shares would be relieved that the share price has rebounded 28% in the last...Artículo de análisis • Aug 27
Calculating The Intrinsic Value Of CareDx, Inc (NASDAQ:CDNA)
Key Insights The projected fair value for CareDx is US$10.87 based on 2 Stage Free Cash Flow to Equity Current share...Actualización de narrativa • Aug 15
Rising Organ Transplant Needs Will Reshape Diagnostics Despite Challenges
CareDx’s consensus price target was reduced from $27.50 to $22.20, primarily due to heightened reimbursement risk stemming from the proposed Palmetto MolDx LCD and recent share price volatility, despite operational stability and some analysts seeing undervaluation at current levels. Analyst Commentary Ongoing uncertainty surrounding the Palmetto MolDx draft Local Coverage Determination (LCD), which proposes to limit reimbursement for certain transplant tests.Artículo de análisis • Jul 23
The Market Doesn't Like What It Sees From CareDx, Inc's (NASDAQ:CDNA) Revenues Yet As Shares Tumble 32%
The CareDx, Inc ( NASDAQ:CDNA ) share price has fared very poorly over the last month, falling by a substantial 32...Artículo de análisis • May 02
Is There An Opportunity With CareDx, Inc's (NASDAQ:CDNA) 28% Undervaluation?
Key Insights The projected fair value for CareDx is US$20.92 based on 2 Stage Free Cash Flow to Equity Current share...
Nueva narrativa • Mar 24
AlloMap Testing And OPTN Project Will Expand Markets Despite Risks
CareDx's growth fueled by expanded testing services and strategic investments aims to improve margins and revenue cycle management.Seeking Alpha • Mar 13
CareDx: Some Litigation Clouds Have Cleared
Summary CareDx, Inc. has cleared up some litigation and legal challenges since I last looked at this diagnostic concern last summer. The company continues to post solid revenue growth and has a rock-solid balance sheet. FY2024 saw progress on numerous fronts, and CDNA delivered margin increases and a massive increase in adjusted EBITDA. An updated analysis around CareDx, Inc. follows in the paragraphs below. Read the full article on Seeking AlphaArtículo de análisis • Mar 11
Why CareDx's (NASDAQ:CDNA) Earnings Are Weaker Than They Seem
We didn't see CareDx, Inc's ( NASDAQ:CDNA ) stock surge when it reported robust earnings recently. We decided to have a...Seeking Alpha • Dec 30
CareDx: Too Risky For Me
Summary CareDx faces regulatory challenges and lacks a durable competitive advantage in a fragmented and competitive market, with no clear moat to protect its position, leading to a poor risk-reward profile. Management changes and negative employee reviews indicate potential internal instability, casting doubt on future company performance despite their innovative products. Despite strong gross margins and a solid balance sheet, CareDx's inability to turn a profit and questionable capital allocation methods make it a sell. Read the full article on Seeking AlphaArtículo de análisis • Nov 05
The Market Doesn't Like What It Sees From CareDx, Inc's (NASDAQ:CDNA) Revenues Yet As Shares Tumble 26%
CareDx, Inc ( NASDAQ:CDNA ) shareholders won't be pleased to see that the share price has had a very rough month...Seeking Alpha • Sep 29
CareDx Resolves Key Issues: Poised For Growth In Transplant Diagnostics
Summary CDNA has resolved corporate instability and insurance issues, showing potential for sustainable growth with innovative transplant testing services like AlloSure, AlloMap, and HeartCare. CDNA's products are supported by scientific literature and recent Medicare coverage expansions, enhancing their market potential and revenue growth prospects. The appointment of CEO John W. Hanna provides stable leadership and strategic direction for long-term objectives. Despite ongoing legal disputes with Natera, revised processes may protect future AlloSure revenues. CDNA's valuation is high, but its expanding revenues and recent insurance coverage wins justify a "Buy" rating for investors aware of inherent biotech risks. Read the full article on Seeking AlphaArtículo de análisis • Aug 01
CareDx, Inc's (NASDAQ:CDNA) Share Price Boosted 34% But Its Business Prospects Need A Lift Too
Despite an already strong run, CareDx, Inc ( NASDAQ:CDNA ) shares have been powering on, with a gain of 34% in the last...Rentabilidad de los accionistas
| CDNA | US Biotechs | Mercado US | |
|---|---|---|---|
| 7D | 6.8% | 6.3% | 4.2% |
| 1Y | 290.1% | 40.9% | 20.6% |
Rentabilidad vs. Industria: CDNA superó a la industria US Biotechs, que obtuvo un rendimiento del 40.9% el año pasado.
Rentabilidad vs. Mercado: CDNA superó al mercado US, que obtuvo un rendimiento del 20.6% el año pasado.
Volatilidad de los precios
| CDNA volatility | |
|---|---|
| CDNA Average Weekly Movement | 13.0% |
| Biotechs Industry Average Movement | 10.1% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Precio estable de las acciones: El precio de las acciones de CDNA ha sido volátil durante los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de CDNA(13%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de las acciones de US.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1998 | 763 | John Hanna | caredx.com |
CareDx, Inc. ofrece soluciones para mejorar los resultados de los pacientes trasplantados y promover la salud de los órganos en los Estados Unidos y a escala internacional. La empresa ofrece AlloSure Kidney, una solución de ADN libre de células derivadas de donantes (dd-cfDNA) para pacientes trasplantados de riñón; AlloMap Heart, una solución de perfiles de expresión génica para pacientes trasplantados de corazón; AlloSure Heart, una solución de dd-cfDNA para pacientes trasplantados de corazón; y AlloSure Lung, una solución de dd-cfDNA para pacientes trasplantados de pulmón. También ofrece HeartCare, que proporciona información sobre distintos procesos biológicos, como la quiescencia inmunitaria, la lesión activa, el rechazo celular agudo y el rechazo mediado por anticuerpos; HistoMap Kidney, una solución que identifica el rechazo de aloinjertos y el tipo de rechazo en tejido de biopsia de trasplante renal; y AlloHeme, una prueba de monitorización que predice la recaída en pacientes con leucemia mieloide aguda y síndromes mielodisplásicos.
Resumen de fundamentos de CareDx, Inc.
| Estadísticas fundamentales de CDNA | |
|---|---|
| Capitalización bursátil | US$2.42b |
| Beneficios(TTM) | US$111.01m |
| Ingresos (TTM) | US$458.09m |
21.8x
Ratio precio-beneficio (PE)5.3x
Ratio precio-ventas (PS)¿Está CDNA sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de CDNA | |
|---|---|
| Ingresos | US$458.09m |
| Coste de los ingresos | US$134.76m |
| Beneficio bruto | US$323.33m |
| Otros gastos | US$212.32m |
| Beneficios | US$111.01m |
Últimos beneficios comunicados
Jun 30, 2026
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | 2.15 |
| Margen bruto | 70.58% |
| Margen de beneficio neto | 24.23% |
| Ratio deuda/patrimonio | 0% |
¿Cómo se ha desempeñado CDNA a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/08/09 17:47 |
| Precio de las acciones al final del día | 2026/08/07 00:00 |
| Beneficios | 2026/06/30 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
CareDx, Inc. está cubierta por 16 analistas. 7 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Paul Knight | Brean Capital Historical (Janney Montgomery) |
| Mark Massaro | BTIG |
| William Bonello | Craig-Hallum Capital Group LLC |